MSF Access Campaign at WHA 2023 wrap-up with Francisco Viegas

Diagnostics Resolution at 2023 WHA with Stijn Deborggraeve

Access to Ebola treatments with Julien Potet

MSF welcomes WHA resolution on strengthening diagnostic testing in low- and middle-income countries

MSF at the opening of the 2023 World Health Assembly, with Shailly Gupta

MSF warned that access to point-of-care CD4 tests for HIV are under threat because Abbott and Becton Dickinson have decided to stop production

Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed

MSF Access Campaign answers three questions on the challenges accessing liposomal amphotericin B (L-AmB), a key drug for treating the deadly HIV opportunistic infection cryptococcal meningitis.

MSF appreciates EC pharma legislation proposal to improve transparency by industry and the granting of compulsory licenses on medicines in the EU.

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

For World Immunization Week 2023, MSF calls on Gavi to expand its policy to catch up young children on missed vaccinations.

With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

MSF called on governments and donors to speed up access to diagnostic tests, and shorter, safer and more effective treatments, for DR-TB.

MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions

MSF statement at the Fourth meeting of the Intergovernmental Negotiating Body (INB) for a World Health Organization instrument on pandemic prevention, preparedness and response.

Gavi's new CEO must prioritise catch-up vaccinations for young children, and more inclusive decision-making.

MSF Statement on EB152/13 - Strengthening clinical trials

MSF Statement on EB152/7 - Substandard and falsified medical products

MSF Statement on EB152/5 - Strengthening diagnostics capacity